Kalaris Therapeutics, Inc.

Kalaris Therapeutics is a United States-based biopharmaceutical company focused on developing innovative cell therapies for autoimmune diseases and immune-mediated disorders. The company is dedicated to pioneering novel treatments that address the underlying causes of these conditions, aiming to provide long-term benefits for patients. Kalaris Therapeutics utilizes its proprietary technologies to engineer and manufacture cell-based therapies with enhanced efficacy and safety profiles. By targeting specific immune cells and pathways, Kalaris Therapeutics seeks to restore immune balance and alleviate disease symptoms. The company's research and development efforts are centered on advancing its pipeline of cell therapy candidates through preclinical and clinical stages, with the goal of bringing transformative therapies to patients in need. As a publicly traded company on the NASDAQ exchange, Kalaris Therapeutics is committed to advancing the field of cell therapy and improving patient outcomes in the autoimmune disease space.